ERBB2 and neoplasm: Recent evidence suggests that the superior efficacy of T-DXd in HER2-low tumors is partly attributable to this mechanism; unlike conventional ADCs, the payload of T-DXd is released extracellularly after cleavage, exerting a bystander effect not only on neighboring tumor cells but potentially on the stromal components as well [53].